The stuttering treatment market consists of various speech therapies and medications that help reduce stuttering and improve speech fluency. Stuttering, also known as stammering, is a speech disorder characterized by repetitions, prolongations of sounds, syllables or words as well as interruptions in the fluency of speech. It is estimated that around 70 million people across the world have a stuttering disorder with the condition more prevalent in males than females.

The Global Stuttering Market is estimated to be valued at USD 51.5 million in 2024 and is expected to reach USD 150.1 million by 2031, growing at a compound annual growth rate (CAGR) of 11.3% from 2024 to 2031.

Key players operating in the stuttering treatment market are Johnson & Johnson Services Inc., AstraZeneca, Plc., GlaxoSmithKline Plc., Merck & Co. Inc., Pfizer Inc., Mylan N.V., Teva Pharmaceutical Industries Ltd., Sanofi S.A., Bausch Health Companies Inc.

Stuttering Market primarily involves specific speech therapy techniques and drug therapies that help reduce severity and frequency of stuttering. Speech therapy focuses on techniques like gradual increase of length and complexity of phrases, controlled breathing, altering speech rhythm and preventing stuttering behaviors. Fluoxetine, Botulinum toxin type A injection and Dextromethorphan + Quinidine are some drugs approved by FDA for short term use in stuttering treatment.

Get more insights on: Stuttering Market

Get this Report in Japanese Language: 吃音市場

Get this Report in Korean Language: 말더듬는 시장